Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series.

IF 6.8 1区医学 Q1 ONCOLOGY

NPJ Precision Oncology Pub Date : 2025-10-09 DOI:10.1038/s41698-025-01115-0

Camila B Xavier, Mohamed A Gouda, Apostolia M Tsimberidou

{"title":"Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series.","authors":"Camila B Xavier, Mohamed A Gouda, Apostolia M Tsimberidou","doi":"10.1038/s41698-025-01115-0","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy has substantially changed the landscape of cancer. We present five patients with advanced cancer who had failed standard-of-care therapies, participated in clinical trials with anti-CTLA4/anti-PD1 therapy, and had prolonged progression-free survival (PFS): Pt1: microsatellite stable (MSS) rectal adenocarcinoma (34+ months); Pt2: high grade neuroendocrine carcinoma (68 months); Pt3: MSS colon adenocarcinoma (38+ months); Pt4: deficient mismatch repair (dMMR) prostate adenocarcinoma (68+ months); Pt5: high-grade neuroendocrine carcinoma (69+ months). Grade 3 immune-related adverse events (irAEs; n = 4) were treated successfully, allowing further treatment with the anti-PD1 therapy. Positron-emission tomography (PET)/computed tomography (CT) scans demonstrated complete response in 3 of 4 patients whose CT scans had shown partial response. These cases highlight the exceptional outcomes of selected patients with advanced cancer treated with immunotherapy and exemplify the value of personalized patient monitoring/management of irAEs while assessing response to immunotherapy. Ongoing trials evaluate biomarkers that predict response and toxicity associated with immunotherapy.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"322"},"PeriodicalIF":6.8000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511611/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Precision Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41698-025-01115-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immunotherapy has substantially changed the landscape of cancer. We present five patients with advanced cancer who had failed standard-of-care therapies, participated in clinical trials with anti-CTLA4/anti-PD1 therapy, and had prolonged progression-free survival (PFS): Pt1: microsatellite stable (MSS) rectal adenocarcinoma (34+ months); Pt2: high grade neuroendocrine carcinoma (68 months); Pt3: MSS colon adenocarcinoma (38+ months); Pt4: deficient mismatch repair (dMMR) prostate adenocarcinoma (68+ months); Pt5: high-grade neuroendocrine carcinoma (69+ months). Grade 3 immune-related adverse events (irAEs; n = 4) were treated successfully, allowing further treatment with the anti-PD1 therapy. Positron-emission tomography (PET)/computed tomography (CT) scans demonstrated complete response in 3 of 4 patients whose CT scans had shown partial response. These cases highlight the exceptional outcomes of selected patients with advanced cancer treated with immunotherapy and exemplify the value of personalized patient monitoring/management of irAEs while assessing response to immunotherapy. Ongoing trials evaluate biomarkers that predict response and toxicity associated with immunotherapy.

查看原文本刊更多论文

晚期实体瘤患者对双重免疫检查点阻断的长期反应：一个病例系列。

免疫疗法已经极大地改变了癌症的面貌。我们报告了5例标准治疗失败的晚期癌症患者，他们参加了抗ctla4 /抗pd1治疗的临床试验，并延长了无进展生存期（PFS）： Pt1：微卫星稳定（MSS）直肠腺癌（34个月以上）；Pt2：高级别神经内分泌癌（68个月）；Pt3: MSS结肠腺癌（38+月）；Pt4：缺陷错配修复（dMMR）前列腺腺癌（68+月）；Pt5：高级别神经内分泌癌（69+月）。3级免疫相关不良事件（irae; n = 4）得到成功治疗，允许进一步使用抗pd1治疗。正电子发射断层扫描(PET)/计算机断层扫描（CT）显示，4例CT扫描显示部分反应的患者中有3例完全缓解。这些病例强调了接受免疫治疗的晚期癌症患者的特殊结果，并举例说明了在评估免疫治疗反应时对irae进行个性化患者监测/管理的价值。正在进行的试验评估预测免疫治疗反应和毒性的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Precision Oncology ONCOLOGY-

CiteScore

9.90

自引率

1.30%

发文量

审稿时长

18 weeks

期刊介绍： Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.